proton therapy


Also found in: Acronyms, Wikipedia.

proton therapy

A type of particle therapy that uses a beam of protons to irradiate diseased tissue.
Mentioned in ?
References in periodicals archive ?
In order to sustain the market growth and to increase the use of proton therapy as an efficient cancer treatment, the PT industry will need to better involve the medical community with stronger marketing to grow the referencing of patients toward proton therapy centers.
USPRwire, Wed Dec 13 2017] United States Proton Therapy market is expected to reach nearly US$ 1 Billion, potentially US$ 7 Billion by 2025.
Nicolas Bronchart, Executive Vice President, Research & Development Proton Therapy, added IBA is once again pushing the limit of proton therapy and together with Beaumont's Proton Therapy Center we will bring a technology that could offer further benefits for patients.
In the Proton therapy the technology is different - its machine is three stories high and weighting up of 100 tons consists of special housing within a treatment facility to hold the equipment and convey the proton beams.
This new centre, scheduled to open by early 2019, will have a single-room setup utilising the MEVION S250i Proton Therapy System with HYPERSCAN technology.
The hospital will install multi-room ProBeam proton therapy system manufactured by Varian with four 360 gantries.
The agreement with Mevion provides us the opportunity to integrate the industry's most compact proton therapy system, the MEVION S250 Series, with our slim, multi- purpose in-room CBCT system, providing large field-of-view, cutting edge acquisition speed, spatial resolution, and outstanding low contrast visibility at very low doses, said Heinz Deutschmann, chief executive officer and founder of medPhoton.
Two NHS Proton Therapy Centres are due to open in the next two years in London and Manchester.
For some diagnoses, such as prostate cancer, paranasal sinus cancer or base of skull tumours, proton therapy is much better than conventional photon radiotherapy," says Dr Kubes.
Since we started clinical use in 2008, it has not only helped Hitachi expand into global market of proton therapy systems, but also reminds us of the importance of strengthening the collaboration with MD Anderson to enhance cancer treatment.
Concord Medical will remain the second largest shareholder of the MD Anderson Proton Therapy Center, with MD Anderson retaining its 51% majority interest.
This report covers the present scenario and the growth prospects of the Global Proton Therapy market for the period 2014-2018.

Full browser ?